| 1 | Asundexian versus Apixaban in Patients with Atrial Fibrillation | 34.6 | 103 | Citations (PDF) |
| 2 | Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation | 4.0 | 2 | Citations (PDF) |
| 3 | Large simple randomized controlled trials—from drugs to medical devices: lessons from recent experience | 2.0 | 4 | Citations (PDF) |
| 4 | Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation | 2.3 | 4 | Citations (PDF) |
| 5 | Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use | 11.2 | 2 | Citations (PDF) |
| 6 | Alcohol Intake and Cardiovascular Outcomes in Patients With Atrial Fibrillation: <scp>RE</scp>‐<scp>LY AF</scp> Registry Analysis | 1.0 | 2 | Citations (PDF) |
| 7 | Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation | 2.9 | 2 | Citations (PDF) |
| 8 | Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) | 62.3 | 11 | Citations (PDF) |
| 9 | Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial | 4.0 | 1 | Citations (PDF) |
| 10 | Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure | 10.0 | 217 | Citations (PDF) |
| 11 | Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure | 4.0 | 5 | Citations (PDF) |
| 12 | Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial | 4.0 | 12 | Citations (PDF) |
| 13 | Patients’ experiences of clinical trial participation involving a product remotely assessing study drug adherence | 1.2 | 0 | Citations (PDF) |
| 14 | Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry | 2.2 | 3 | Citations (PDF) |
| 15 | SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study | 6.2 | 4 | Citations (PDF) |
| 16 | Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation | 18.1 | 9 | Citations (PDF) |
| 17 | Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study | 1.4 | 14 | Citations (PDF) |
| 18 | SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART | 7.0 | 13 | Citations (PDF) |
| 19 | 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) | 2.2 | 1,686 | Citations (PDF) |
| 20 | European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics | 2.2 | 179 | Citations (PDF) |
| 21 | The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design | 7.4 | 15 | Citations (PDF) |
| 22 | Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference | 2.0 | 159 | Citations (PDF) |
| 23 | Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart) | 3.7 | 14 | Citations (PDF) |
| 24 | Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation | 2.2 | 47 | Citations (PDF) |
| 25 | Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores | 2.9 | 9 | Citations (PDF) |
| 26 | Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation | 2.0 | 9 | Citations (PDF) |
| 27 | Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction | 2.9 | 27 | Citations (PDF) |
| 28 | Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI | 4.0 | 29 | Citations (PDF) |
| 29 | Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease | 5.5 | 15 | Citations (PDF) |
| 30 | Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation | 5.5 | 40 | Citations (PDF) |
| 31 | Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex | 18.1 | 322 | Citations (PDF) |
| 32 | Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society | 2.0 | 51 | Citations (PDF) |
| 33 | Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study | 62.3 | 272 | Citations (PDF) |
| 34 | Previous history of hyperthyroidism in emergency department patients with
atrial fibrillation does not increase the risk of thromboembolism and death | 0.5 | 0 | Citations (PDF) |
| 35 | Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model | 2.9 | 16 | Citations (PDF) |
| 36 | Serum Neurofilament Light Chain in Patients With Atrial Fibrillation | 4.0 | 22 | Citations (PDF) |
| 37 | Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper | 4.1 | 102 | Citations (PDF) |
| 38 | SGLT2 inhibition reduces myocardial oxygen consumption | 2.4 | 9 | Citations (PDF) |
| 39 | Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data | 3.7 | 1 | Citations (PDF) |
| 40 | Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study | 18.1 | 146 | Citations (PDF) |
| 41 | Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study | 2.0 | 33 | Citations (PDF) |
| 42 | Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale | 2.9 | 25 | Citations (PDF) |
| 43 | Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials | 4.0 | 37 | Citations (PDF) |
| 44 | 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) | 2.2 | 8,378 | Citations (PDF) |
| 45 | Risk markers of incident atrial fibrillation in patients with coronary heart disease | 2.9 | 12 | Citations (PDF) |
| 46 | Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study | 4.6 | 54 | Citations (PDF) |
| 47 | Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study | 62.3 | 401 | Citations (PDF) |
| 48 | Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | 3.1 | 7 | Citations (PDF) |
| 49 | 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation | 2.0 | 861 | Citations (PDF) |
| 50 | Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation | 18.1 | 43 | Citations (PDF) |
| 51 | The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE‐DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials) | 2.0 | 3 | Citations (PDF) |
| 52 | Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation | 3.8 | 26 | Citations (PDF) |
| 53 | Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction | 1.2 | 2 | Citations (PDF) |
| 54 | Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis | 1.9 | 2 | Citations (PDF) |
| 55 | LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry | 4.0 | 8 | Citations (PDF) |
| 56 | Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference | 2.0 | 59 | Citations (PDF) |
| 57 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial | 4.0 | 3 | Citations (PDF) |
| 58 | Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial | 2.0 | 4 | Citations (PDF) |
| 59 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation | 2.3 | 4 | Citations (PDF) |
| 60 | Weight gain and blood pressure | 2.2 | 13 | Citations (PDF) |
| 61 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial) | 1.8 | 16 | Citations (PDF) |
| 62 | Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemicHeart, 2020, 106, 1812-1818 | 4.0 | 48 | Citations (PDF) |
| 63 | Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation | 2.2 | 107 | Citations (PDF) |
| 64 | Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials | 6.6 | 8 | Citations (PDF) |
| 65 | Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation | 4.0 | 55 | Citations (PDF) |
| 66 | Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI | 2.0 | 5 | Citations (PDF) |
| 67 | Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials | 3.8 | 21 | Citations (PDF) |
| 68 | Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI TrialDrugs, 2020, 80, 995-1005 | 11.4 | 13 | Citations (PDF) |
| 69 | Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis | 2.0 | 21 | Citations (PDF) |
| 70 | Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care | 0.7 | 8 | Citations (PDF) |
| 71 | Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study | 2.3 | 1 | Citations (PDF) |
| 72 | Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | 4.8 | 22 | Citations (PDF) |
| 73 | Risk of ischemic stroke and utility of CHA<sub>2</sub>DS<sub>2</sub>‐VASc score in women and men with atrial fibrillation | 2.0 | 39 | Citations (PDF) |
| 74 | Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI | 3.1 | 12 | Citations (PDF) |
| 75 | Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease | 1.1 | 2 | Citations (PDF) |
| 76 | Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)—An initial pilot-study of a randomized clinical trial | 2.8 | 73 | Citations (PDF) |
| 77 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial | 2.2 | 74 | Citations (PDF) |
| 78 | Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial | 2.9 | 13 | Citations (PDF) |
| 79 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes | 3.1 | 16 | Citations (PDF) |
| 80 | Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation | 3.1 | 9 | Citations (PDF) |
| 81 | Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial | 4.0 | 22 | Citations (PDF) |
| 82 | Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial | 2.2 | 152 | Citations (PDF) |
| 83 | Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials | 2.2 | 146 | Citations (PDF) |
| 84 | Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | 34.6 | 20 | Citations (PDF) |
| 85 | A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score | 2.2 | 111 | Citations (PDF) |
| 86 | Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis | 2.9 | 15 | Citations (PDF) |
| 87 | Design of DISCO—Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study | 2.9 | 25 | Citations (PDF) |
| 88 | Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention | 4.0 | 14 | Citations (PDF) |
| 89 | Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference | 2.0 | 104 | Citations (PDF) |
| 90 | Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG—Short- and long-term survival | 2.9 | 41 | Citations (PDF) |
| 91 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary | 2.0 | 213 | Citations (PDF) |
| 92 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation | 2.2 | 1,794 | Citations (PDF) |
| 93 | Effects of sauna bath on heart failure: A systematic review and meta‐analysis | 2.0 | 22 | Citations (PDF) |
| 94 | Response by Oldgren and Sundström to Letter Regarding Article, “Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study” | 18.1 | 1 | Citations (PDF) |
| 95 | Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation | 2.3 | 71 | Citations (PDF) |
| 96 | Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS | 1.1 | 15 | Citations (PDF) |
| 97 | Effects of dabigatran according to age in atrial fibrillationHeart, 2017, 103, 1015-1023 | 4.0 | 85 | Citations (PDF) |
| 98 | Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions | 3.0 | 77 | Citations (PDF) |
| 99 | Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial | 2.9 | 49 | Citations (PDF) |
| 100 | Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New‐Onset Atrial Fibrillation After Acute Myocardial Infarction | 4.0 | 13 | Citations (PDF) |
| 101 | Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation | 1.1 | 92 | Citations (PDF) |
| 102 | 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS | 0.5 | 299 | Citations (PDF) |
| 103 | Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events | 18.1 | 148 | Citations (PDF) |
| 104 | Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial | 2.0 | 19 | Citations (PDF) |
| 105 | Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | 34.6 | 1,241 | Citations (PDF) |
| 106 | Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time | 4.0 | 27 | Citations (PDF) |
| 107 | Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study | 2.3 | 32 | Citations (PDF) |
| 108 | D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy | 4.1 | 36 | Citations (PDF) |
| 109 | D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy | 4.1 | 37 | Citations (PDF) |
| 110 | Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial | 2.9 | 32 | Citations (PDF) |
| 111 | All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcomeHeart, 2016, 102, 926-933 | 4.0 | 93 | Citations (PDF) |
| 112 | The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study | 62.3 | 447 | Citations (PDF) |
| 113 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS | 1.4 | 823 | Citations (PDF) |
| 114 | Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study | 62.3 | 271 | Citations (PDF) |
| 115 | Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy | 1.5 | 23 | Citations (PDF) |
| 116 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS | 2.2 | 6,082 | Citations (PDF) |
| 117 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS | 2.0 | 3,691 | Citations (PDF) |
| 118 | Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation | 18.1 | 89 | Citations (PDF) |
| 119 | Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting | 2.0 | 66 | Citations (PDF) |
| 120 | Dabigatran etexilate and reduction in serum apolipoprotein B | 4.0 | 34 | Citations (PDF) |
| 121 | Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial | 2.3 | 42 | Citations (PDF) |
| 122 | The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation | 2.2 | 401 | Citations (PDF) |
| 123 | Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation | 2.0 | 19 | Citations (PDF) |
| 124 | A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference | 2.0 | 134 | Citations (PDF) |
| 125 | Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure | 4.1 | 217 | Citations (PDF) |
| 126 | Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non–ST-Segment Elevation Myocardial Infarction | 16.6 | 38 | Citations (PDF) |
| 127 | Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial | 2.2 | 74 | Citations (PDF) |
| 128 | Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation | 2.0 | 992 | Citations (PDF) |
| 129 | Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation | 2.9 | 124 | Citations (PDF) |
| 130 | Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis” | 18.1 | 2 | Citations (PDF) |
| 131 | Author reply | 2.0 | 2 | Citations (PDF) |
| 132 | Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation | 18.1 | 376 | Citations (PDF) |
| 133 | Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries | 18.1 | 350 | Citations (PDF) |
| 134 | Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyHeart, 2014, 100, 1193-1200 | 4.0 | 50 | Citations (PDF) |
| 135 | Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? | 2.6 | 10 | Citations (PDF) |
| 136 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study | 18.1 | 199 | Citations (PDF) |
| 137 | Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding | 18.1 | 245 | Citations (PDF) |
| 138 | Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial | 18.1 | 462 | Citations (PDF) |
| 139 | European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation | 2.0 | 741 | Citations (PDF) |
| 140 | Biomarkers in atrial fibrillation: a clinical review | 2.2 | 276 | Citations (PDF) |
| 141 | Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation | 2.3 | 66 | Citations (PDF) |
| 142 | Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial” | 18.1 | 2 | Citations (PDF) |
| 143 | New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis | 2.2 | 180 | Citations (PDF) |
| 144 | Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy” | 18.1 | 2 | Citations (PDF) |
| 145 | Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden | 2.2 | 57 | Citations (PDF) |
| 146 | EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary† | 2.2 | 374 | Citations (PDF) |
| 147 | Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial | 18.1 | 348 | Citations (PDF) |
| 148 | Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation | 18.1 | 384 | Citations (PDF) |
| 149 | Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin | 18.1 | 529 | Citations (PDF) |
| 150 | Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial | 9.7 | 183 | Citations (PDF) |
| 151 | Dabigatran Versus Warfarin in Patients With Atrial Fibrillation | 18.1 | 453 | Citations (PDF) |
| 152 | Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation | 18.1 | 1,081 | Citations (PDF) |
| 153 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial | 2.2 | 496 | Citations (PDF) |
| 154 | Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIAHeart, 2010, 96, 1451-1457 | 4.0 | 27 | Citations (PDF) |
| 155 | Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention | 2.3 | 62 | Citations (PDF) |
| 156 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | 62.3 | 937 | Citations (PDF) |
| 157 | Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran | 2.9 | 306 | Citations (PDF) |
| 158 | Dabigatran versus Warfarin in Patients with Atrial Fibrillation | 34.6 | 10,494 | Citations (PDF) |
| 159 | Risk prediction in chest pain patients by biochemical markers including estimates of renal function | 2.2 | 12 | Citations (PDF) |
| 160 | Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial | 2.9 | 18 | Citations (PDF) |
| 161 | Xa inhibition and coagulation activity—the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals | 2.9 | 6 | Citations (PDF) |
| 162 | Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome | 2.9 | 18 | Citations (PDF) |
| 163 | The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial | 2.2 | 59 | Citations (PDF) |
| 164 | Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment | 2.2 | 38 | Citations (PDF) |
| 165 | Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial | 2.2 | 28 | Citations (PDF) |
| 166 | Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients | 2.2 | 57 | Citations (PDF) |
| 167 | The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment | 2.3 | 25 | Citations (PDF) |
| 168 | An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease | 2.9 | 61 | Citations (PDF) |
| 169 | Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease | 4.1 | 13 | Citations (PDF) |
| 170 | Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary | 2.2 | 210 | Citations (PDF) |
| 171 | Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study | 18.1 | 1 | Citations (PDF) |
| 172 | Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI | 3.2 | 0 | Citations (PDF) |
| 173 | Prevalence and prediction of masked uncontrolled hypertension in patients recently hospitalized for myocardial infarction | 2.5 | 0 | Citations (PDF) |
| 174 | Long-term prognostic impact of one-year change in left ventricular function after a myocardial infarction: insights from the REBUS cohort 0, 4, | | 0 | Citations (PDF) |
| 175 | Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure | 4.0 | 0 | Citations (PDF) |
